Through a steadfast commitment to research, technology and state-of-the-art manufacturing, Abbott has developed a diverse portfolio of breakthrough diabetes products designed to meet the needs of each unique patient. Our innovative product development program is responsible for several groundbreaking technologies. Keep looking to our dedicated teams for the next generation of highly innovative and effective glucose monitoring products. We aim to set the standard for helping patients and healthcare providers to potentially achieve the best health outcomes.

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with central nervous system (CNS) disorders. Our vision is to become the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with CNS disorders. Our history is rooted in science and strong leadership in CNS research. We have set ourselves apart by transforming our novel discoveries into important drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. The Company currently has two FDA-approved therapies. INBRIJA® is approved for the intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also developed and markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, indicated to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

As a world leader in allergy immunotherapy, ALK works to improve quality of life for the many allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication, by developing products that provide long-lasting relief. The company has approximately 2,000 employees, with subsidiaries, production facilities and distributors worldwide. ALK is headquartered in Denmark and listed on NASDAQ Copenhagen (OMX: ALK B).

Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression.

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product availably by prescription.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, with a presence in approximately 100 countries and regions worldwide. Our innovative medicines have reached millions of people in the fight against serious illnesses, with a focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises.

Ascendis Pharma is applying its innovative TransConTM technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives.

Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, rare disease endocrinology product candidates in clinical development. We have also established oncology as our second therapeutic area of focus.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Avadel Pharmaceuticals plc is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Bausch & Lomb, Inc. is the preeminent global technology-based healthcare company for the eye, dedicated to helping consumers see, look and feel better through innovative technology and design. Its core businesses include soft and rigid gas permeable contact lenses, lens-care products, ophthalmic surgical and pharmaceutical products. Today, Bausch & Lomb is the only company with product offerings for every major aspect of refractive surgery. The company’s new technologies provide even more options to help surgeons meet a wider variety of patients’ vision correction.

Bioventus is a global leader of innovations for active healing. Through a combination of internal product development, product/business acquisition, and distribution agreements, we will bring to market products which address a growing need for clinically effective, cost efficient, minimally invasive medical treatments, that engage and enhance the body’s natural healing processes.

Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the management of opioid use disorder (OUD) by partnering with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential. If applicable: Visit https://braeburnrx.com to learn more.
Connect with Braeburn on LinkedIn at https://linkedin.com/company/Braeburn

At Bristol Myers Squibb, we believe in the power of science to address some of the most challenging diseases of our time. Our focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history. We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms.

Calliditas Therapeutics is a specialty pharmaceutical company headquartered in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a two-step unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US.

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.

We deliver comprehensive strategies to engage globally and locally through one partner. From clinical to commercial and every point between, we strive for accelerated speed to market and better outcomes.

Cencora has a proven history of partnership, bringing complex and transformative therapies to market.

We offer:
- A full continuum of strategy consulting services, providing the right resources at the right time
- Vast provider reach and patient services experience enabling deep connection and support across key stakeholders
- Proven expertise guiding therapies through the commercialization journey within a global footprint
- A team of SMEs eager to innovate and flex to meet your unique needs

Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures.

Chiesi USA is a specialty pharmaceutical company committed to research, development, production and commercialization of innovative products in the areas of cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. Our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Chiesi USA, as they strive to build their company, their family and their community.

Coherus BioSciences is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Coherus was founded in 2010 to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.

CVS is headquartered in Woonsocket, RI, the largest pharmacy health care provider in the U.S. and has integrated offerings across the spectrum of pharmacy care that involves more than 246,000 colleagues across all 50 states, Washington, D.C., Puerto Rico and Brazil. Millions of times a day, we’re helping people on their path to better health—from advising on prescriptions to helping manage chronic and specialty conditions. Because we’re present in so many moments, big and small, we have an active, supportive role in shaping the future of health care

We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function, like heart failure, hypertrophic cardiomyopathies (HCM), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). By focusing on impacting the mechanics of muscle with investigational medicines that may improve strength, power, or performance, we aspire to develop new treatment options that may dramatically improve the lives and functionality of people living with debilitating diseases.We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.

Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering our community to take control of diabetes

Satisfying diverse healthcare needs around the world ~ Around the world there are still many diseases for which no effective treatments exist and many patients who do not have adequate access to the medicines they need. As a global pharmaceutical company addressing these unmet medical needs, Eisai is committed to making contributions to better healthcare for patients and their families around the world through its business activities.

embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.

EMD Serono, Inc. is committed to discovering and developing medicines that address unmet medical needs. EMD Serono focuses its business in the areas of neurology, reproductive health, metabolic endocrinology, oncology, and autoimmune disease, integrating innovative science with comprehensive patient support systems to improve lives. Visit us at www.emdserono.com.

Emerging Therapy Solutions® (ETS) helps healthcare payers – including reinsurance and stop-loss payers, health plans and self-funded employers – manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies.

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. Exelixis was founded and incorporated in 1994 and we are based in South San Francisco, California. Exelixis is dedicated to improving the care of, and outcomes for patients with cancer.

Express Scripts, the pharmacy benefits management (PBM) business of Evernorth Health Services has a simple mission: To improve clinical outcomes and lower the cost of prescription drugs for the one in three Americans we serve. Driven and proactive, our dedicated teams leverage data analytics and insights to anticipate and address tough challenges while reducing plan and member costs. We deliver the care and attention members need—and the simpler health care experience they deserve. To learn more, please visit our website.

As a privately-owned, biopharma company, Ferring focuses on developing life-changing innovations that help people live better lives. Grounded in a 70-year commitment to science and research, we are relentless in our pursuit of therapies that help people build families, stay healthy, and fight disease. We’re committed to being the world-leading, most trusted healthcare company in reproductive medicine and maternal health, and a leader in specialty areas within gastroenterology and orthopaedics. With that ambition in mind, we’re dedicated to following the science, conducting exhaustive research, and going where others may not—which means that people will always come first.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Genentech, Inc. is a leading biotechnology company focusing on the discovery, development, manufacture, and marketing of pharmaceuticals for significant, unmet medical needs. Genentech’s managed care specialists are committed to enhancing the quality and delivery of patient care by working with managed care organizations to find effective solutions to health care issues.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Health Delegates delivers pharmacy and medical rebates, formulary solutions, and comprehensive reporting including our proprietary client portal, HD View TM. Our team of experts, fueled by our independent P&T Committee, balances clinical and financial factors to create cost-effective, clinically superior, and PBM agnostic solutions. Our experts at our Illuma Advisors subsidiary partner closely with healthcare entities to uncover the gritty details which are leveraged to drive to strategic solutions and offering which promote growth.

Our mission is to improve human health by unlocking the power of genome.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. The company’s first commercial product, Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor, is approved by the FDA to treat two rare blood disorders--first approved in November 2011 Jakafi received a subsequent U.S. approval in December 2014.

Ipsen is a leading biopharmaceutical group dedicated to improving lives through innovative medicines in oncology , neuroscience and rare diseases. Ipsen’s mission, “innovation for patient care”, highlights the Group’s determination to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. As well as our dedication to improving the lives of patients, Ipsen is also firmly committed to protecting the environment and to supporting civil society and the communities in which we operate. The Group is pledged to promote ethical, responsible and transparent professional practices.

Ironwood Pharmaceuticals is a patient-focused, biopharmaceutical company on a mission to push the boundaries of the gastrointestinal (GI) field by advancing the treatment of GI diseases and redefining the standard of care for millions of patients.

Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation.

Kroger Prescription Plans has provided comprehensive Pharmacy Benefits Management services since 1993. We combine transparency and highly competitive pricing to drive lower costs for clients and their members, while at the same time delivering exceptional customer service. Our plans are flexible and adaptable. Kroger Prescription Plans is focused on improving the health & wellness of our customers. We are committed to advancing health, reducing costs and improving the efficacy of any client’s health strategy.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquarted in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.

MedImpact is the PBM that puts clients and consumers first. For 30 years, it has had a single mission: To make pharmacy benefits affordable, understandable, and transparent. Today, MedImpact’s team and technology serve many large employers and plans, and more than 55 million consumers in the US and around the world. Learn more at medimpact.com or follow us on Twitter @MedImpact.

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work wtih customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

Independent for over 70 years, Milliman delivers market-leading services and solutions to clients worldwide. With no agenda, other than getting it right.Through a team of professionals ranging from actuaries to clinicians, technology specialists to plan administrators, we offer unparalleled expertise in employee benefits, investment consulting, healthcare, life insurance and financial services, and property and casualty insurance.

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Neurelis is a unique company focused on therapies for disorders involving the central nervous system. Our company is built on a foundation of passion and progress. This passion fuels our drive to successfully deliver innovative therapies that have the potential to change the lives of patients, caregivers, and healthcare providers. Neurelis is a neuroscience-based specialty pharmaceutical company dedicated to enhancing therapeutic benefit and addressing unmet needs in patient care.

Novo Nordisk Inc. is a focused healthcare company. With a broad diabetes product portfolio, including innovative products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. Worldwide, Novo Nordisk employs an estimated 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's global headquarters is located in Denmark where the company began more than 80 years ago with the North American affiliate headquartered in Princeton, NJ.

OncoHealth is dedicated to helping health plans, employers, oncologists, and patients navigate the physical, mental, and financial complexities of cancer. Focused 100% on oncology, OncoHealth’s market-leading software and services platform combines oncology value management services with virtual cancer care to ensure people with cancer are getting the most appropriate treatment and supported through the duration of their treatment with services including 24/7 oncology nursing, mental health, nutrition, and resource navigation. To learn more, visit www.oncohealth.us.

Organon Pharmaceuticals USA Inc. is the U.S. affiliate of N.V. Organon, a renowned international ethical pharmaceutical company. Organon – with shared head offices in Roseland, N.J., USA and Oss, The Netherlands – creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its cores therapeutic fields: reproductive medicine, psychiatry and anaesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. Akzo Nobel is an international company active in the areas of pharmaceuticals, coatings and chemicals with approximately 61,000 employees and operations in over 80 countries.

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI).

Outcomes® unites technology and clinical relationships through a connected healthcare network to drive better outcomes. As a leading patient-centric technology business, we unite pharmacies, payers, and pharmaceutical companies through patient engagement solutions, tailored tools for the future pharmacy, and advanced workflow optimization. Our comprehensive offerings benefit a nationwide network of 48,000 community, chain, and grocery pharmacies, and more than 70 million patients.

As one of the world’s leading healthcare companies, Pfizer has developed and brought to market medicines for humans and animals for over 150 years. Our portfolio includes more category-leading medicines than any other company – treatments that are helping countless people everyday to ease arthritis and nerve pain, manage depression, fight diabetes and cancer and control hypertension. Our portfolio of innovative medicines currently includes treatments for more than a dozen disease areas and we are targeting unmet medical needs through state-of-the-art research and development.

We know that healthcare is more than a business—it’s a mission-and our products can only help people if they can get them. That’s why we are deeply committed to enhancing access to high-quality healthcare. This year, through innovative partnership programs, Pfizer is giving product donations for patients in need around the world and building the infrastructure necessary to ensure that the medicines get to those who need it most.

The value of medicine. The benefits of research. The commitment to help meet the needs of those in need. At Pfizer, we dedicate ourselves to humanity’s quest for longer, healthier, happier lives through innovation in pharmaceutical, consumer and animal health products.

We are your advocate in drug management. For over 25 years PSG has been singularly focused on helping our clients navigate the complex and ever-changing challenges of drug management. Through our leading pharmacy intelligence and technologies, we save our clients billions of dollars every year with an unwavering commitment to serving as your advocate and strategic partner. Our mission is to relentlessly advocate for our clients as we partner together to develop innovative drug management solutions that deliver exceptional insights, financial and clinical value.

Precision for Medicine, headquartered in Bethesda, MD, is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization.

Precision for Value supports commercial excellence for global pharmaceutical and life sciences clients through the proficient demonstration of product value and outcomes. With locations in New York City, New Jersey, Chicago, Boston, Connecticut, and Indianapolis, Precision for Value’s teams provide clients with services grounded in decades of industry knowledge, demonstrated analytics proficiency, and marketing and communications prowess—making Precision for Value the preferred strategic partner in the industry.

Precision Advisors combines unrivaled real-world market experience with thought leadership and industry expertise to provide insight, strategy and advice to innovative life science companies. Headquartered in Cambridge, Massachusetts, Precision Advisors’ unmatched team of expert advisors encompass all areas of the commercialization spectrum including strategy consulting, managed markets, health economics, clinical research and analytics.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Samsung Bioepis is a biopharmaceutical company dedicated to unlocking the potential of biosimilar medicines and transforming the way biologic therapies are brought to patients. Our mission is reflected in our name, bio-epis; literally meaning life (“bio”) and science (“episteme”) in Greek. We want to enhance the lives of patients through our pioneering and innovative use of science and technology.

Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Sandoz prides itself on thinking differently. While developing and manufacturing high-quality affordable medicines is core to who we are and what we do, our mission is even greater: We endeavor to make these medicines available to everyone, everywhere. Our portfolio of approximately 1 100 molecules is already available to more than 90% of the world’s population and we continue to work hard to further increase global access.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. We are developing several product candidates in neurology and psychiatry to address unmet medical needs and opportunities in epilepsy, attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Taiho Oncology, Inc. a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho’s oral oncology pipeline consists of both novel antimetabolic agents and selectively targeted agents.

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Teva Pharmaceuticals has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,600 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products.
©2023 Teva Neuroscience, Inc. NPS-40577 March 2023

TOLMAR is a fully integrated company focused on the development, approval, and commercialization of specialty pharmaceutical products, including a line of generic dermatology products where TOLMAR is an established leader, and specialty injectable oncology products. Invention, development, and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer has established TOLMAR as a leader dedicated to the urology community, providers, and patients. TOLMAR has 24 FDA-approved products.

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients.